• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

Six guidelines to navigate the Aduhelm controversy and (hopefully) help patients with Mild Cognitive Impairment and early-stage Alzheimer’s Disease

October 13, 2021 by Kaiser Health News

The approval of a con­tro­ver­sial new drug for Alzheimer’s dis­ease, Aduhelm, is shin­ing a spot­light on mild cog­ni­tive impair­ment — prob­lems with mem­o­ry, atten­tion, lan­guage or oth­er cog­ni­tive tasks that exceed changes expect­ed with nor­mal aging.

After ini­tial­ly indi­cat­ing that Aduhelm could be pre­scribed to any­one with demen­tia, the Food and Drug Admin­is­tra­tion now spec­i­fies that the pre­scrip­tion drug be giv­en to indi­vid­u­als with mild cog­ni­tive impair­ment or ear­ly-stage Alzheimer’s, the groups in which the med­ica­tion was studied.

Yet this nar­row­er rec­om­men­da­tion rais­es ques­tions. What does a diag­no­sis of mild cog­ni­tive impair­ment mean? Is Aduhelm appro­pri­ate for all peo­ple with mild cog­ni­tive impair­ment, or only some? And who should decide which patients qual­i­fy for treat­ment: demen­tia spe­cial­ists or pri­ma­ry care physicians?

Con­tro­ver­sy sur­rounds Aduhelm because its effec­tive­ness hasn’t been proved, its cost is high (an esti­mat­ed $56,000 a year, not includ­ing expens­es for imag­ing and month­ly infu­sions), and its poten­tial side effects are sig­nif­i­cant (41% of patients in the drug’s clin­i­cal tri­als expe­ri­enced brain swelling and bleeding).

Fur­ther­more, an FDA advi­so­ry com­mit­tee strong­ly rec­om­mend­ed against Aduhelm’s approval, and Con­gress is inves­ti­gat­ing the process lead­ing to the FDA’s deci­sion. Medicare is study­ing whether it should cov­er the med­ica­tion, and the Depart­ment of Vet­er­ans Affairs has declined to do so under most circumstances.

Clin­i­cal tri­als for Aduhelm exclud­ed peo­ple over age 85; those tak­ing blood thin­ners; those who had expe­ri­enced a stroke; and those with car­dio­vas­cu­lar dis­ease or impaired kid­ney or liv­er func­tion, among oth­er con­di­tions. If those cri­te­ria were broad­ly applied, 85% of peo­ple with mild cog­ni­tive impair­ment would not qual­i­fy to take the med­ica­tion, accord­ing to a new research let­ter in the Jour­nal of the Amer­i­can Med­ical Association.

Giv­en these con­sid­er­a­tions, care­ful­ly select­ing patients with mild cog­ni­tive impair­ment who might respond to Aduhelm is “becom­ing a pri­or­i­ty,” said Dr. Ken­neth Lan­ga, a pro­fes­sor of med­i­cine, health man­age­ment and pol­i­cy at the Uni­ver­si­ty of Michigan.

Dr. Ronald Petersen, who directs the Mayo Clinic’s Alzheimer’s Dis­ease Research Cen­ter, said, “One of the biggest issues we’re deal­ing with since Aduhelm’s approval is, ‘Are appro­pri­ate patients going to be giv­en this drug?’”

Here’s what peo­ple should know about mild cog­ni­tive impair­ment based on a review of research stud­ies and con­ver­sa­tions with lead­ing experts.

1. The Basics. Mild cog­ni­tive impair­ment is often referred to as a bor­der­line state between nor­mal cog­ni­tion and demen­tia. But this can be mis­lead­ing. Although a sig­nif­i­cant num­ber of peo­ple with mild cog­ni­tive impair­ment even­tu­al­ly devel­op demen­tia — usu­al­ly Alzheimer’s dis­ease — many do not.

Cog­ni­tive symp­toms — for instance, dif­fi­cul­ties with short-term mem­o­ry or plan­ning — are often sub­tle but they per­sist and rep­re­sent a decline from pre­vi­ous func­tion­ing. Yet a per­son with the con­di­tion may still be work­ing or dri­ving and appear entire­ly nor­mal. By def­i­n­i­tion, mild cog­ni­tive impair­ment leaves intact a person’s abil­i­ty to per­form dai­ly activ­i­ties independently.

Accord­ing to an Amer­i­can Acad­e­my of Neu­rol­o­gy review of dozens of stud­ies, pub­lished in 2018, mild cog­ni­tive impair­ment affects near­ly 7% of peo­ple ages 60 to 64, 10% of those 70 to 74 and 25% of 80- to 84-year-olds.

2. The Caus­es. Mild cog­ni­tive impair­ment can be caused by bio­log­i­cal process­es (the accu­mu­la­tion of amy­loid beta and tau pro­teins and changes in the brain’s struc­ture) linked to Alzheimer’s dis­ease. Between 40% and 60% of peo­ple with mild cog­ni­tive impair­ment have evi­dence of Alzheimer’s‑related brain pathol­o­gy, accord­ing to a 2019 review.

But cog­ni­tive symp­toms can also be caused by oth­er fac­tors, includ­ing small strokes; poor­ly man­aged con­di­tions such as dia­betes, depres­sion and sleep apnea; respons­es to med­ica­tions; thy­roid dis­ease; and unrec­og­nized hear­ing loss. When these issues are treat­ed, nor­mal cog­ni­tion may be restored or fur­ther decline forestalled.

3. The Sub­types. Dur­ing the past decade, experts have iden­ti­fied four sub­types of mild cog­ni­tive impair­ment. Each sub­type appears to car­ry a dif­fer­ent risk of pro­gress­ing to Alzheimer’s dis­ease, but pre­cise esti­mates haven’t been established.

Peo­ple with mem­o­ry prob­lems and mul­ti­ple med­ical issues who are found to have changes in their brain through imag­ing tests are thought to be at great­est risk. “If bio­mark­er tests con­verge and show abnor­mal­i­ties in amy­loid, tau and neu­rode­gen­er­a­tion, you can be pret­ty cer­tain a per­son with MCI has the begin­nings of Alzheimer’s in their brain and that dis­ease will con­tin­ue to evolve,” said Dr. Howard Chertkow, chair­per­son for cog­ni­tive neu­rol­o­gy and inno­va­tion at Bay­crest, an aca­d­e­m­ic health sci­ences cen­ter in Toron­to that spe­cial­izes in care for old­er adults.

4. The Diag­no­sis. Usu­al­ly, this process begins when old­er adults tell their doc­tors that “some­thing isn’t right with my mem­o­ry or my think­ing” — a so-called sub­jec­tive cog­ni­tive com­plaint. Short cog­ni­tive tests can con­firm whether objec­tive evi­dence of impair­ment exists. Oth­er tests can deter­mine whether a per­son is still able to per­form dai­ly activ­i­ties successfully.

More sophis­ti­cat­ed neu­ropsy­cho­log­i­cal tests can be help­ful if there is uncer­tain­ty about find­ings or a need to bet­ter assess the extent of impair­ment. But “there is a short­age of physi­cians with exper­tise in demen­tia — neu­rol­o­gists, geri­a­tri­cians, geri­atric psy­chi­a­trists” — who can under­take com­pre­hen­sive eval­u­a­tions, said Kathryn Phillips, direc­tor of health ser­vices research and health eco­nom­ics at the Uni­ver­si­ty of Cal­i­for­nia-San Fran­cis­co School of Pharmacy.

The most impor­tant step is tak­ing a care­ful med­ical his­to­ry that doc­u­ments whether a decline in func­tion­ing from an individual’s base­line has occurred and inves­ti­gat­ing pos­si­ble caus­es such as sleep pat­terns, men­tal health con­cerns and inad­e­quate man­age­ment of chron­ic con­di­tions that need attention.

Mild cog­ni­tive impair­ment “isn’t nec­es­sar­i­ly straight­for­ward to rec­og­nize, because people’s think­ing and mem­o­ry changes over time [with advanc­ing age] and the ques­tion becomes ‘Is this some­thing more than that?’” said Dr. Zoe Arvan­i­takis, a neu­rol­o­gist and direc­tor of Rush University’s Rush Mem­o­ry Clin­ic in Chicago.

More than one set of tests is need­ed to rule out the pos­si­bil­i­ty that some­one per­formed poor­ly because they were ner­vous or sleep-deprived or had a bad day. “Admin­is­ter­ing tests to peo­ple over time can do a pret­ty good job of iden­ti­fy­ing who’s actu­al­ly declin­ing and who’s not,” Lan­ga said.

5. Pro­gres­sion. Mild cog­ni­tive impair­ment doesn’t always progress to demen­tia, nor does it usu­al­ly do so quick­ly. But this isn’t well under­stood. And esti­mates of pro­gres­sion vary, based on whether patients are seen in spe­cial­ty demen­tia clin­ics or in com­mu­ni­ty med­ical clin­ics and how long patients are followed.

A review of 41 stud­ies found that 5% of patients treat­ed in com­mu­ni­ty set­tings each year went on to devel­op demen­tia. For those seen in demen­tia clin­ics — typ­i­cal­ly, patients with more seri­ous symp­toms — the rate was 10%. The Amer­i­can Acad­e­my of Neurology’s review found that after two years 15% of patients were observed to have dementia.

Pro­gres­sion to demen­tia isn’t the only path peo­ple fol­low. A siz­able por­tion of patients with mild cog­ni­tive impair­ment — from 14% to 38% — are dis­cov­ered to have nor­mal cog­ni­tion upon fur­ther test­ing. Anoth­er por­tion remains sta­ble over time. (In both cas­es, this may be because under­ly­ing risk fac­tors — poor sleep, for instance, or poor­ly con­trolled dia­betes or thy­roid dis­ease — have been addressed.) Still anoth­er group of patients fluc­tu­ate, some­times improv­ing and some­times declin­ing, with peri­ods of sta­bil­i­ty in between.

“You real­ly need to fol­low peo­ple over time — for up to 10 years — to have an idea of what is going on with them,” said Dr. Oscar Lopez, direc­tor of the Alzheimer’s Dis­ease Research Cen­ter at the Uni­ver­si­ty of Pittsburgh.

6. Spe­cial­ists ver­sus gen­er­al­ists. Only peo­ple with mild cog­ni­tive impair­ment asso­ci­at­ed with Alzheimer’s should be con­sid­ered for treat­ment with Aduhelm, experts agreed. “The ques­tion you want to ask your doc­tor is, ‘Do I have MCI [mild cog­ni­tive impair­ment] due to Alzheimer’s dis­ease?’” Chertkow said.

Because this med­ica­tion tar­gets amy­loid, a sticky pro­tein that is a hall­mark of Alzheimer’s, con­fir­ma­tion of amy­loid accu­mu­la­tion through a PET scan or spinal tap should be a pre­req­ui­site. But the pres­ence of amy­loid isn’t deter­mi­na­tive: One-third of old­er adults with nor­mal cog­ni­tion have been found to have amy­loid deposits in their brains.

Because of these com­plex­i­ties, “I think, for the ear­ly roll­out of a com­plex drug like this, treat­ment should be over­seen by spe­cial­ists, at least ini­tial­ly,” said Petersen of the Mayo Clin­ic. Arvan­i­takis of Rush Uni­ver­si­ty agreed. “If some­one is real­ly and tru­ly inter­est­ed in try­ing this med­ica­tion, at this point I would rec­om­mend it be done under the care of a psy­chi­a­trist or neu­rol­o­gist or some­one who real­ly spe­cial­izes in cog­ni­tion,” she said.

– By Judith Gra­ham. This sto­ry was pro­duced by KHN, a nation­al news­room that pro­duces in-depth jour­nal­ism about health issues. Togeth­er with Pol­i­cy Analy­sis and Polling, KHN is one of the three major oper­at­ing pro­grams at KFF (Kaiser Fam­i­ly Foundation). 

News in Context:

  • Study: Few­er than 1% of geri­atric patients with cog­ni­tive com­plaints met Aduhelm research tri­al cri­te­ria. What can we expect about its real-world safety?
  • Vet­er­ans Affairs won’t cov­er Biogen’s new “Alzheimer’s drug” giv­en con­cerns over safe­ty and lack of evidence
  • Alzheimer’s & Demen­tia researchers chal­lenge FDA’s approval of Aduhelm giv­en lack of evi­dence for beta-amy­loid as a marker
  • Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can)

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health Tagged With: Aduhelm, Alzheimer’s Disease, attention-problems, brain bleeding, brain swelling, cognitive problems, dementia, dementia specialists, early-stage Alzheimer’s, Food and Drug Administration, language problems, memory problems, mild-cognitive-impairment, neuropsychological, neuropsychological-tests, normal cognition, primary care physicians, tests

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,619 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2022 SharpBrains. All Rights Reserved - Privacy Policy